GSK plc (LON:GSK) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of GSK plc (LON:GSK - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is GBX 1,862.50 ($25.21).

Several research analysts have commented on the company. Shore Capital reaffirmed a "buy" rating on shares of GSK in a report on Wednesday, April 30th. JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of GSK in a report on Friday, March 28th.

Insider Activity

In other news, insider Wendy Becker bought 536 shares of the firm's stock in a transaction that occurred on Thursday, March 20th. The stock was acquired at an average cost of GBX 1,515 ($20.51) per share, with a total value of £8,120.40 ($10,992.83). Also, insider Emma Walmsley sold 5,473 shares of the business's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of GBX 1,449 ($19.62), for a total value of £79,303.77 ($107,355.85). 1.61% of the stock is owned by company insiders.

GSK Price Performance

Shares of LON GSK traded down GBX 3 ($0.04) during mid-day trading on Monday, hitting GBX 1,425.50 ($19.30). 6,218,375 shares of the stock traded hands, compared to its average volume of 15,373,808. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. GSK has a twelve month low of GBX 1,242.50 ($16.82) and a twelve month high of GBX 1,793.50 ($24.28). The company has a market cap of £57.84 billion, a PE ratio of 23.03, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The firm has a 50 day simple moving average of GBX 1,400.95 and a two-hundred day simple moving average of GBX 1,395.12.

GSK (LON:GSK - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.61) EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, equities research analysts forecast that GSK will post 175.980975 EPS for the current fiscal year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.